Sentences with phrase «cancer tumours targeted»
But Deng says that the lung - cancer tumours targeted by their trial are not easily accessible.
https://www.scientificamerican.com/ Not exact matches
Our work suggests that studying PI (3,4) P2 - regulated processes may reveal why PTEN is such a powerful tumour suppressor and may also help us to identify new therapeutic targets in PTEN - mutated cancers.»
«Our results suggest that we've been looking at these cancer drugs the wrong way — as tumour - targeting drugs — instead of what we now feel is their most important biological role: as immune stimulating therapy.»
Breast cancer patients who have radiotherapy targeted at the original tumour site experience fewer side effects five years after treatment than those who have whole breast radiotherapy, and their cancer is just as unlikely to return, according to trial results published in The Lancet.
This tumour - targeting makes it a promising ally in the fight against cancer.
Cardiff University scientists have developed a novel anti-cancer stem cell agent capable of targeting aggressive tumour forming cells common to breast, pancreas, colon and prostate cancers.
Around 15 per cent of women with breast cancer have this form of the disease, in which tumour cells lack the three receptors that most drugs target.
«Pancreatic cancer is extremely hard to treat by chemotherapy, so this finding is important because vitamin A targets the non-cancerous tissue and makes the existing chemotherapy more effective, killing the cancer cells and shrinking tumours.
A COMPOUND that slows the proliferation of triple - negative breast cancer cells in lab tests could lead to the first drugs to target this aggressive type of tumour.
A cancer biologist at the University of Turin in Italy, he had been studying targeted therapies — drugs tailored to the mutations that drive the growth of a tumour.
The researchers, at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, say their test is the first developed for a precision prostate cancer therapy targeted at specific genetic faults within tuCancer Research, London, and The Royal Marsden NHS Foundation Trust, say their test is the first developed for a precision prostate cancer therapy targeted at specific genetic faults within tucancer therapy targeted at specific genetic faults within tumours.
Our data show that cancer cells without BRCA1 have more than one «Achilles heel,» and so there are more ways to target cancers and therefore to prevent tumours becoming resistant to treatment.»
Understanding the molecular mechanisms underlying Aurora kinase - overexpressing tumours will help in the design of targeted and personalised cancer therapy,» said Dr Linda Chuang, Senior Research Scientist at CSI Singapore, who is the first author of the study.
If these could be targeted to tumours — by attaching them to antibodies that recognise cancer cells, for instance — it would then be possible to destroy the malignant cells» DNA using lower doses of radiation or drugs.
Targeting the tumour blood supply seems to be a promising way to increase the effectiveness of chemotherapy in cervical cancer, Symonds says.
«MCL - 1 is found at high levels in a number of blood cancers and also many solid tumours, so there has been a strong drive to develop potential anti-cancer compounds that target MCL - 1,» he said.
Research fields are diverse, including basic research on cell proliferation, analysis of tumour cells and tissues to detect gene mutations, and identification of potential therapeutic targets in cancer.
Although it might be useful to reduce that collateral damage for some applications, he says it could prove beneficial in others — in a cancer treatment, for example, wiping out «bystander» RNA as well as target RNA might offer a more effective way to fight a tumour.
A trained robotic surgeon experienced in the treatment of prostate, bladder and kidney cancer, Assoc Prof Chia said, «For anticancer drugs to achieve their best effectiveness, they need to penetrate into the tumour efficiently in order to reach the cystoplasm of all the cancer cells that are being targeted without affecting the normal cells.
«This is because the stress led to poor function against the cancer by T - cells, which are very important in the immune system's control and surveillance of tumours and are a major target in many immunotherapy treatments.»
TNBC is deadly because, unlike other types of breast cancers such as estrogen receptor (ER) positive or HER2 amplified breast tumours which have effective targeted therapy, TNBC tumours do not respond to targeted therapy.
The virus, code - named JX - 954, targets two genes involved in cancer cell growth and blood supply, which show increased activity in tumours.
In the future, scientists hope to target stem - cell - like cells within cancers that may be responsible for most of the growth of some tumours, and evade existing drugs.
Angiogenesis inhibition is commonly targeted in cancer treatment development that aims to starve tumours of the nutrients necessary for their survival.
It could also lead to the development of new breast cancer drugs to target tumours with a specific genetic make - up.
Researchers are studying how to use tumour - specific neoantigens in vaccines to help the body mount an immune response targeted at the cancer.
These drugs can be targeted to interfere with signalling within the tumour microenvironment or activate other processes which will kill the cancer cells.
Meguro, Japan (Scicasts)- Tumour detection using targeted fluorescent imaging probes is a promising technology that takes advantage of specific molecular events occurring in cancer tissues.
We target tumours by exploring how the proteins found on the cancer cell surface can be utilised to inhibit growth or kill tumours.
My team is investigating the utility of Jak inhibitors to target colorectal tumours and the role of DCLK1 as a driver of gastric cancer.
Willet, Mills, and their colleagues believe the discovery that cells in different organs go through the same process to become proliferative could lead to new potential targets for cancer treatment because the factors that initiate tumours could be the same in multiple organs.
Our research combines diverse techniques ranging from genomics, computational biology, tumour imaging, in vitro and in vivo functional models to study biological and clinical phenotypes.The proteins produced by these genes may serve as targets for novel chemotherapy drugs and other cancer treatments, or imaging scans.
We have identified a novel amino acid transporter, SLC6A14, as a drug target for cancer treatment; this transporter has functional features superior to those of SLC1A5, SLC7A5 and SLC7A11 to support tumour growth.
Targeting CTCs, the cells responsible for spreading cancer, is important because they carry information from the primary tumour that can inform treatment; however, they are outnumbered by a billion - to - one by normal cells in a patient» blood and are therefore extremely challenging to capture.
Despite these successes two major problems remain: first, the majority of lung cancer patients have tumours without mutations in targetable genes and; second, all patients eventually develop resistance to treatment with these targeted agents.
Areas of focus include: understanding how tumour - reactive T cells and B cells promote patient survival in cancer; defining the effects of standard treatments on tumor immunity; and using genomic approaches to identify novel tumour mutations that can serve as target antigens for immunotherapy.
Several studies have demonstrated the feasibility of molecular screening of tumour samples for matching patients with cancer to targeted therapies.
The increasing number of drugs targeting specific proteins implicated in tumourigenesis and the commercial promotion of relatively affordable genome - wide analyses has led to an increasing expectation among patients with cancer that they can now receive effective personalised treatment based on the often complex genomic signature of their tumour.
Within the scope of personalized medicine, this technology presents immense possibilities for testing patient - derived multicellular tumour spheroids / organoids (comprising cancer cells, stromal cells, cancer stem cells and / or immune cells) for disease / biomarker - oriented drug activity and profiling using single - and pair-wise standard / targeted drug combinations.
Homozygous deletions are rare in cancers and often target tumour suppressor genes.
iTeos is focused on expanding the benefits of immunotherapy for cancer patients by developing a proprietary pipeline targeting IDO1, A2A, TIGIT immune checkpoint and non-immunogenic («cold») tumours.